Updated

Novo Nordisk shares fell sharply Monday after the Danish drugmaker laid out its 2030 growth strategy, which failed to reassure investors hoping for a turnaround. The company is seeking to prove it can compete in an increasingly crowded weight-loss drug market it helped pioneer. The stock decline reflects investor skepticism about Novo's ability to sustain growth as competition intensifies from rivals in the GLP-1 drug space.